A Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).
Pamela L KunzNoah T GrahamPaul J CatalanoHalla S NimeiriGeorge A FisherTeri A LongacreCarlos J SuarezBrock A MartinJames C YaoMatthew H KulkeAndrew E HendifarJames C ShanksManisha H ShahMark M ZalupskiEdmond L SchmulbachDiane L ReidyJonathan R StrosbergPeter J O'DwyerAl Bowen BensonPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
The combination of capecitabine/temozolomide was associated with a significant improvement in PFS compared to temozolomide alone in patients with advanced pancreatic NETs. The median PFS and RR observed with capecitabine/temozolomide are the highest reported in a randomized study for pancreatic NETs. MGMT deficiency was associated with response and, although, routine MGMT testing is not recommended, it can be considered for select patients in need of objective response. NCT01824875.
Keyphrases
- newly diagnosed
- neuroendocrine tumors
- end stage renal disease
- phase ii study
- locally advanced
- metastatic breast cancer
- metastatic colorectal cancer
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- clinical practice
- clinical trial
- squamous cell carcinoma
- radiation therapy
- patient reported outcomes
- open label